DBV Technologies CEO to Present at Goldman Sachs Healthcare Conference
Event summary
- DBV Technologies CEO Daniel Tassé to participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026, at 9:20 AM ET in Miami, FL.
- Live webcast available on DBV Technologies' Investor website, with archived replay accessible for 90 days post-event.
- DBV Technologies is a late-stage biopharmaceutical company focused on food allergy treatments using its proprietary VIASKIN® patch technology.
- Company's shares traded on Euronext Paris and Nasdaq Capital Market.
The big picture
DBV Technologies' participation in the Goldman Sachs Healthcare Conference underscores its strategic focus on advancing food allergy treatments. The company's VIASKIN® patch technology represents a novel approach to immunotherapy, addressing a significant unmet medical need. The event provides a platform for DBV to showcase its progress and engage with key stakeholders in the biopharmaceutical industry.
What we're watching
- Clinical Progress
- The pace at which DBV Technologies advances its VIASKIN Peanut clinical trials in toddlers and children will be critical to watch.
- Market Positioning
- How DBV Technologies positions itself against competitors in the food allergy treatment space following the conference.
- Investor Sentiment
- Whether the presentation at the Goldman Sachs conference will influence investor sentiment and stock performance.